Baxter Immunoglobulin Fails to Aid Alzheimer’s Patients

Baxter International Inc.’s Gammagard failed to help patients with Alzheimer’s disease in a late-stage study, adding to a string of failures to develop a treatment for the most common form of dementia.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.